Glycopyrrolate as inhalation for treating sialorrhea in Parkinson’s Disease
Objective: To evaluate the safety, tolerability and effect of glycopyrrolate inhalations in PD patients with sialorrhea. Background: Sialorrhea is reported in up to 60 percent…Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea
Objective: To assess the onset of action for rimabotulinumtoxinBinjections in the salivary glands for the treatment of sialorrhea. Background: Sialorrhea (drooling) causes significant morbidity including impaired oral…Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea
Objective: To assess the safety, tolerability and effectiveness of repeated rimabotulinumtoxinB injections in adults with troublesome sialorrhea over a period of 1 year. Background: Sialorrhea…RimbotulinumtoxinB in the treatment of adult sialorrhea
Objective: To assess efficacy, safety and tolerability of repeat injections of rimabotulinumtoxinBfor the treatment of sialorrhea. Background: Sialorrhea (drooling) can cause significant morbidity in several neurological disorders,…Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea
Objective: To assess the duration of rimabotulinumtoxinB action in the management of sialorrhea. Background: In neurological disorders, sialorrhea (drooling) is both prevalent and problematic. Local…Effects of Botulinum Toxin treatment for sialorrhea in patients with cerebral palsy
Objective: To evaluate the benefits of treatment of drooling with Botulinum Toxin Type A (AbobotulinumtoxinA) in patients with cerebral palsy. Background: Patients with cerebral palsy…Efficacy of incobotulinumtoxinA in patients with sialorrhea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP): Results of the SIAXI study
Objective: The pivotal double-blind, randomised Phase III SIAXI study (NCT02091739), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U for sialorrhea. Co-primary endpoints…Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions
Objective: SIAXI (NCT02091739), a pivotal double-blind, randomised, placebo-controlled study with a 48-week extension period (EP), assessed the efficacy and safety of incobotulinumtoxinA 75 U or…Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhea
Objective: SIAXI (NCT02091739), a pivotal double-blind, randomised, placebo-controlled study with an extension period (EP), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U…Saliva changes and the oral health in Parkinson´s disease
Objective: The aim of this study was to determine the risk of change in the oral microflora and oral health in PD patients. Background: Parkinson…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.